RT Journal Article
SR Electronic
T1 Clinical characteristics of 101 non-surviving hospitalized patients with COVID-19—A single center, retrospective study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.04.20031039
DO 10.1101/2020.03.04.20031039
A1 Shi, Qiao
A1 Zhao, Kai-Liang
A1 Yu, Jia
A1 Feng, Jia-Rui
A1 Zhao, Kai-Ping
A1 Zhang, Xiao-Yi
A1 Chen, Xiao-Yan
A1 Hu, Peng
A1 Hong, Yu-Pu
A1 Li, Man
A1 Liu, Fang
A1 Chen, Chen
A1 Wang, Wei-Xing
YR 2020
UL http://medrxiv.org/content/early/2020/03/06/2020.03.04.20031039.abstract
AB OBJECTIVE To study the clinical characteristics of non-surviving hospitalized patients with confirmed COVID-19 in Wuhan, China, and tracked the causes of the death.DESIGN Retrospective case series.SETTING Two campus of Renmin Hospital of Wuhan University in Wuhan, China, and is responsible for the treatments for COVID-19 assigned by the government.PARTICIPANTS 101 non-surviving hospitalized patients with confirmed COVID-19. Data were collected from 1 January 2020 to 15 February 2020.MAIN OUTCOME MEASURES Clinical data were collected using a standardized case report form. If information was not clear, the investigators in Wuhan contacted the doctor responsible for treating the patients or family members of non-survivors for clarification.RESULTS Of 121 died patients with confirmed COVID-19, 101 cases with relatively complete medical records were included. The median age of the 101 non-survivors were 71 years (IQR, 59-80), 60 (59.41%) were men. 82 (81.19%) had fever, 82 (81.19%) had 1 or more comorbidities including hypertension (59 [58.42%]) and diabetes (22 [21.78%]) etc. The median course from hospitalization to death was 4d (IQR, 2-7d). Of 101 died patients, 100 (99.01%) suffered respiratory failure, 53 (52.48%) developed acute myocardial injury, acute kidney and liver injury occurred in 23 (22.77%) and 18 (17.82%) patients, respectively. Chest computed tomographic scans of non-survivors showed vast and fused ground-glass shadows. Compared to patients who survived 3 days, no statistical difference was noticed on lung severity score (11.91 vs 12.07) in patients who died within 3 days. Furthermore, significant elevated laboratory indicators including hypersensitive troponin (1.98 vs 0.2ng/ml), blood urea nitrogen (15.20 vs 10.08mmol/l), neutrophil count (11.23 vs 6.48×109/L), procalcitonin (2.26 vs 0.58ng/ml) and lactic acid (3.80 vs 2.62 mmol/l) etc. were noted in patients who died with 3 days while PaO2 (54.75 vs 67.45mmHg), CD3% (51.57 vs 60.43%) and CD8% (16.42 vs 23.42%) were significantly depressed.CONCLUSION Older patients (>70 years) with comorbidities had a steeply increased risk of death when they suffered COVID-19. Besides respiratory failure, acute cardiac and kidney damage or failure, secondary to COVID-19, played a crucial role in causing death of patients.WHAT IS ALREADY KNOWN ON THIS TOPIC COVID-19 have deprived thousands of lives and caused global concerns. As of March 4, 2020, a total of 80420 COVID-19 cases in China have been confirmed and over 2900 lost their life. We searched PubMed for articles published up to Mar 4, 2020, using the keywords “2019 novel coronavirus”, “2019-nCoV”, “COVID-19”, or “SARS-CoV-2”. We identified that none study focused on the demographic, clinical characteristics and induced-death factors of non-survivors with COVID-19.WHAT THIS STUDY ADDS The median age of the 101 died patients with confirmed COVID-19 were 71 years (IQR, 59-80). Of 101 died patients, 82 (81.19%) had 1 or more comorbidities including 59 (58.42%) hypertension and 22 (21.78%) diabetes etc. 100 (99.01%) suffered respiratory failure, 53 (52.48%) developed acute myocardial injury, acute kidney and liver injury occurred in 23 (22.77%) and 18 (17.82%) patients, respectively. This indicated that older patients (>70 years) with comorbidities had a steeply increased risk of death when they suffered COVID-19. Besides respiratory failure, acute cardiac and kidney damage or failure, secondary to COVID-19, played a crucial role in causing death of patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementnoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall original data were saved in Renmin Hospital of Wuhan University, Wuhan, China